Literature DB >> 15717696

Fludarabine-based conditioning used in successful bone marrow transplantation from an unrelated donor in a heavily transfused patient with severe aplastic anemia.

Yasunobu Abe, Takamitsu Matsushima, Yoshimichi Tachikawa, Eriko Nagasawa, Junji Nishimura, Hajime Nawata, Koichiro Muta.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15717696     DOI： 10.1532/ijh97.04134

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  8 in total

1.  Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.

Authors:  I F Khouri; R M Saliba; S A Giralt; M S Lee; G J Okoroji; F B Hagemeister; M Korbling; A Younes; C Ippoliti; J L Gajewski; P McLaughlin; P Anderlini; M L Donato; F F Cabanillas; R E Champlin
Journal:  Blood       Date:  2001-12-15       Impact factor: 22.113

2.  Successful non-myeloablative stem cell transplantation for a heavily transfused woman with severe aplastic anemia complicated by heart failure.

Authors:  M Nishio; S Nakao; T Endo; K Fujimoto; H Takashima; T Sakai; A Bacigalupo; T Koike; K Sawada
Journal:  Bone Marrow Transplant       Date:  2001-10       Impact factor: 5.483

3.  Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.

Authors:  P A McSweeney; D Niederwieser; J A Shizuru; B M Sandmaier; A J Molina; D G Maloney; T R Chauncey; T A Gooley; U Hegenbart; R A Nash; J Radich; J L Wagner; S Minor; F R Appelbaum; W I Bensinger; E Bryant; M E Flowers; G E Georges; F C Grumet; H P Kiem; B Torok-Storb; C Yu; K G Blume; R F Storb
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

4.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.

Authors:  S Slavin; A Nagler; E Naparstek; Y Kapelushnik; M Aker; G Cividalli; G Varadi; M Kirschbaum; A Ackerstein; S Samuel; A Amar; C Brautbar; O Ben-Tal; A Eldor; R Or
Journal:  Blood       Date:  1998-02-01       Impact factor: 22.113

Review 5.  Stem cell transplantation for aplastic anemia.

Authors:  George E Georges; Rainer Storb
Journal:  Int J Hematol       Date:  2002-02       Impact factor: 2.490

6.  Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation.

Authors:  H J Deeg; I D Amylon; R E Harris; R Collins; P G Beatty; S Feig; N Ramsay; M Territo; S P Khan; D Pamphilon; J F Leis; S Burdach; C Anasetti; R Hackman; B Storer; B Mueller
Journal:  Biol Blood Marrow Transplant       Date:  2001       Impact factor: 5.742

7.  A fludarabine-based conditioning regimen for severe aplastic anemia.

Authors:  K W Chan; C K Li; L L Worth; K W Chik; S Jeha; M K Shing; P M Yuen
Journal:  Bone Marrow Transplant       Date:  2001-01       Impact factor: 5.483

8.  Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program.

Authors:  Seiji Kojima; Takaharu Matsuyama; Shunichi Kato; Hisato Kigasawa; Ryoji Kobayashi; Atsushi Kikuta; Hisashi Sakamaki; Koichiro Ikuta; Masahiro Tsuchida; Yasutaka Hoshi; Yasuo Morishima; Yoshihisa Kodera
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.